At Anticancer Bioscience, we believe cancer’s greatest strengths can also create its deepest vulnerabilities. Rather than focusing only on the mutations and pathways that drive cancer, we seek the essential dependencies that cancer cells cannot live without – their true Achilles’ heels. By pioneering new concepts and technologies to uncover and exploit these vulnerabilities, we are translating MYC synthetic lethality into biomarker-driven therapies with the potential to transform cancer treatment.